VFA
ALNY icon

Voya Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Voya Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,270
Closed -$210K – 246
2022
Q1 		$210K Buy
+1,270
New +$193K 0.02% 257
2021
Q2 		– Sell
-4,157
Closed -$562K – 259
2021
Q1 		$562K Buy
+4,157
New +$626K 0.02% 398

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Voya Financial Advisors's ALNY Position: Q2 2022 in Review

Voya Financial Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 1,270 shares — an estimated $210K sold.

Voya Financial Advisors first reported a position in ALNY in Q1 2021 and held it in 2 quarters. The position peaked at $562K in Q1 2021. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Voya Financial Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Voya Financial Advisors sold 1,270 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $210K.
  • Voya Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Voya Financial Advisors's Alnylam Pharmaceuticals position peaked at $562K in Q1 2021.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Voya Financial Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.